A global comparison of hepatitis B & C drug pricing.

IF 3.7 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Annals of hepatology Pub Date : 2025-05-23 DOI:10.1016/j.aohep.2025.101928

Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B Jesudian, Robert S Brown, Stephen E Congly

{"title":"A global comparison of hepatitis B & C drug pricing.","authors":"Leah Yao, Xiaohan Ying, Getan Malik, Catherine Tsai, Arun B Jesudian, Robert S Brown, Stephen E Congly","doi":"10.1016/j.aohep.2025.101928","DOIUrl":null,"url":null,"abstract":"Introduction and objectives: Drug pricing is a major driver of healthcare spending in the United States (US) and the cost of medications in the US is up to three time higher than other countries. This cross-sectional study aims to investigate the current price differences between hepatitis B (HBV) and hepatitis C (HCV) antiviral therapies in the US as compared to peer high-income countries.Materials and methods: Publicly available drug formularies for Canada, UK, Japan, France, Germany, Italy, and Australia were used to collect 2024 prices for seven HBV medications (lamivudine, adefovir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate, entecavir, peginterferon alfa-2a, emtricitabine/TDF) and seven HCV medications (sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, sofosbuvir, ribavirin, elbasvir/grazoprevir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir). US prices were obtained from UpToDate®'s listed representative average wholesale price and Medicare Part D 2022 drug prices.Results: US prices for HBV originator medications were on average 4.71x (range 1.99-6.17x) the prices in the peer countries. US generic HBV drug prices for TDF, entecavir, and emtricitabine/TDF were on average 45% cheaper or 0.55x less than the average generic prices in peer countries (range 0.48-0.66x). US originator prices for HCV medications were on average 1.83x the prices in peer countries (range 0.63-2.66x).Conclusions: HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities.","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"101928"},"PeriodicalIF":3.7000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.aohep.2025.101928","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives: Drug pricing is a major driver of healthcare spending in the United States (US) and the cost of medications in the US is up to three time higher than other countries. This cross-sectional study aims to investigate the current price differences between hepatitis B (HBV) and hepatitis C (HCV) antiviral therapies in the US as compared to peer high-income countries.

Materials and methods: Publicly available drug formularies for Canada, UK, Japan, France, Germany, Italy, and Australia were used to collect 2024 prices for seven HBV medications (lamivudine, adefovir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate, entecavir, peginterferon alfa-2a, emtricitabine/TDF) and seven HCV medications (sofosbuvir/velpatasvir, sofosbuvir/ledipasvir, sofosbuvir, ribavirin, elbasvir/grazoprevir, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir). US prices were obtained from UpToDate®'s listed representative average wholesale price and Medicare Part D 2022 drug prices.

Results: US prices for HBV originator medications were on average 4.71x (range 1.99-6.17x) the prices in the peer countries. US generic HBV drug prices for TDF, entecavir, and emtricitabine/TDF were on average 45% cheaper or 0.55x less than the average generic prices in peer countries (range 0.48-0.66x). US originator prices for HCV medications were on average 1.83x the prices in peer countries (range 0.63-2.66x).

Conclusions: HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities.

查看原文本刊更多论文

乙肝和丙肝药物定价的全球比较。

简介和目标：药品定价是美国医疗保健支出的主要驱动因素，美国的药品成本比其他国家高出三倍。本横断面研究旨在调查目前美国乙型肝炎（HBV）和丙型肝炎（HCV）抗病毒治疗与同龄高收入国家相比的价格差异。材料和方法：使用加拿大、英国、日本、法国、德国、意大利和澳大利亚的公开处方收集了2024年7种HBV药物（拉米夫定、阿德福韦、富马酸替诺福韦二氧吡酯（TDF）、富马酸替诺福韦、恩替卡韦、聚干扰素α -2a、恩曲他滨/TDF）和7种HCV药物（索非布韦/维帕他韦、索非布韦/雷地帕韦、索非布韦、利巴韦林、艾尔巴韦/grazoprevir、glecaprevir/pibrentasvir、索非布韦/维帕他韦/voxilaprevir）的价格。美国价格来自UpToDate®列出的代表性平均批发价格和医疗保险D部分2022药品价格。结果：美国HBV源药物的价格平均为同行国家价格的4.71倍（1.99-6.17倍）。TDF、恩替卡韦和恩曲他滨/TDF的美国HBV仿制药价格平均比同行国家的平均仿制药价格便宜45%或0.55倍（范围为0.48-0.66倍）。美国HCV药物的原产价格平均为同行国家价格的1.83倍（范围为0.63-2.66倍）。结论：与其他七个主要工业国家相比，美国HBV和HCV原药的成本明显更高。然而，HBV仿制药的引入降低了美国患者的治疗成本。今后采用国际参考定价可能有助于弥合仍然存在的定价差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of hepatology 医学-胃肠肝病学

CiteScore

7.90

自引率

2.60%

发文量

183

审稿时长

4-8 weeks

期刊介绍： Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.